Investigating crystallization tendency, miscibility, and molecular interactions of drug–polymer systems for the development of amorphous solid dispersions

References

• Sugano K, Okazaki A, Sugimoto S, et al. Solubility and dissolution profile assessment in drug discovery. Drug Metab Pharmacokinet. 2007;22(4):225–254.
   PubMed Web of Science ®Google Scholar
• Williams III RO, Watts AB, Miller DA (Eds.). 2014. Formulating poorly water soluble drugs. (2012th ed). Verlag, New York: Springer.
   Google Scholar
• O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):617–624.
   PubMed Web of Science ®Google Scholar
• Knapik-Kowalczuk J, Gündüz MG, Chmiel K, et al. Molecular dynamics, viscoelastic properties and physical stability studies of a new amorphous dihydropyridine derivative with T-type calcium channel blocking activity. Eur J Pharm Sci. 2020;141:105083.
   PubMed Web of Science ®Google Scholar
• Dhirendra K, Lewis S, Udupa N, et al. Solid dispersions: a review. Pak J Pharm Sci. 2009;22(2):234–246.
   PubMed Web of Science ®Google Scholar
• Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci. 1977;66(1):1–19.
   PubMed Web of Science ®Google Scholar
• Gao Z-G, Choi H-G, Shin H-J, et al. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int J Pharm. 1998;161(1):75–86.
   Web of Science ®Google Scholar
• Calabrò ML, Tommasini S, Donato P, et al. The rutin/beta-cyclodextrin interactions in fully aqueous solution: spectroscopic studies and biological assays. J Pharm Biomed Anal. 2005;36(5):1019–1027.
   PubMed Web of Science ®Google Scholar
• Elder DP, Holm R, Diego H. L d. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility. Int J Pharm. 2013;453(1):88–100.
   PubMedGoogle Scholar
• Cheow WS, Hadinoto K. Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility. J Colloid Interface Sci. 2012;367(1):518–526.
   PubMedGoogle Scholar
• Vinarov Z, Katev V, Radeva D, et al. Micellar solubilization of poorly water-soluble drugs: effect of surfactant and solubilizate molecular structure. Drug Dev Ind Pharm. 2018;44(4):677–686.
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068–1075.
   PubMed Web of Science ®Google Scholar
• Vo CL-N, Park C, Lee B-J. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm. 2013;85(3 Pt B):799–813.
   PubMed Web of Science ®Google Scholar
• Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281–1302.
   PubMed Web of Science ®Google Scholar
• Arun G, Shweta P, Upendra KJ. Formulation and evaluation of ternary solid dispersion of curcumin. Int J Pharm Pharm Sci. 2012;4:360–365.
   Google Scholar
• Meng F, Gala U, Chauhan H. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques. Drug Dev Ind Pharm. 2015;41(9):1401–1415.
   PubMed Web of Science ®Google Scholar
• Baird JA, Taylor LS. Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv Drug Deliv Rev. 2012;64(5):396–421.
   PubMed Web of Science ®Google Scholar
• Hancock BC, York P, Rowe RC. The use of solubility parameters in pharmaceutical dosage form design. Int J Pharm. 1997;148(1):1–21.
   Web of Science ®Google Scholar
• Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res. 2006;23(10):2417–2426.
   PubMed Web of Science ®Google Scholar
• Sarode AL, Sandhu H, Shah N, et al. Hot melt extrusion (HME) for amorphous solid dispersions: Predictive tools for processing and impact of drug-polymer interactions on supersaturation. Eur J Pharm Sci. 2013;48(3):371–384.
   PubMed Web of Science ®Google Scholar
• Khougaz K, Clas SD. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci. 2000;89(10):1325–1334.
   PubMed Web of Science ®Google Scholar
• Marsac PJ, Konno H, Taylor LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res. 2006;23(10):2306–2316.
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Hancock BC, Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci. 1995;84(8):983–986.
   PubMed Web of Science ®Google Scholar
• Chauhan H, Hui‐Gu C, Atef E. Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci. 2013;102(6):1924–1935.
   PubMed Web of Science ®Google Scholar
• Chauhan H, Kuldipkumar A, Barder T, et al. Correlation of inhibitory effects of polymers on indomethacin precipitation in solution and amorphous solid crystallization based on molecular interaction. Pharm Res. 2014;31(2):500–515.
   PubMed Web of Science ®Google Scholar
• Lima ÁAN, Soares-Sobrinho JL, Silva JL, et al. The use of solid dispersion systems in hydrophilic carriers to increase benzonidazole solubility. J Pharm Sci. 2011;100(6):2443–2451.
   PubMed Web of Science ®Google Scholar
• Prasad D, Chauhan H, Atef E. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects. J Pharm Sci. 2014;103(11):3511–3523.
   PubMed Web of Science ®Google Scholar
• Krevelen D. W v. 2012. Properties of polymers. Oxford, UK: Elsevier.
   Google Scholar
• Rowe RC, Sheskey PJ, Quinn ME. 2009. Handbook of pharmaceutical excipients. Grayslake, IL: Pharmaceutical Press.
   Google Scholar
• Marsac PJ, Li T, Taylor LS. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res. 2009;26(1):139–151.
   PubMed Web of Science ®Google Scholar
• Tanaka R, Hattori Y, Horie Y, et al. Characterization of amorphous solid dispersion of pharmaceutical compound with ph-dependent solubility prepared by continuous-spray granulator. Pharmaceutics. 2019;11(4):159.
   Web of Science ®Google Scholar
• Couchman PR, Karasz FE. A classical thermodynamic discussion of the effect of composition on glass-transition temperatures. Macromolecules. 1978;11(1):117–119.
   Web of Science ®Google Scholar
• Gordon M, Taylor JS. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Noncrystalline copolymers. Rubber Chem Technol. 1953;26(2):323–335.
   Google Scholar
• Kwei TK. The effect of hydrogen bonding on the glass transition temperatures of polymer mixtures. J Polym Sci B Polym Lett Ed. 1984;22(6):307–313.
   Web of Science ®Google Scholar
• Chen Y, Liu C, Chen Z, et al. Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions. Mol Pharm. 2015;12(2):576–589.
   PubMedGoogle Scholar
• Ivanisevic I, Bates S, Chen P. Novel methods for the assessment of miscibility of amorphous drug-polymer dispersions. J Pharm Sci. 2009;98(9):3373–3386.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Harris MT, Taylor LS. Modification of crystallization behavior in drug/polyethylene glycol solid dispersions. Mol Pharm. 2012;9(3):546–553.
   PubMed Web of Science ®Google Scholar
• Forster A, Hempenstall J, Tucker I, et al. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm. 2001;226(1-2):147–161.
   PubMed Web of Science ®Google Scholar
• Mahieu A, Willart J-F, Dudognon E, et al. A new protocol to determine the solubility of drugs into polymer matrixes. Mol Pharm. 2013;10(2):560–566.
   PubMed Web of Science ®Google Scholar
• Tao J, Sun Y, Zhang GGZ, et al. Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharm Res. 2009;26(4):855–864.
   PubMed Web of Science ®Google Scholar
• Flory PJ. 1953. Principles of polymer chemistry. Ithaca, NY: Cornell University Press.
   Google Scholar
• Andrews GP, AbuDiak OA, Jones DS. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions. J Pharm Sci. 2010;99(3):1322–1335.
   PubMed Web of Science ®Google Scholar
• Chokshi RJ, Sandhu HK, Iyer RM, et al. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution. J Pharm Sci. 2005;94(11):2463–2474.
   PubMed Web of Science ®Google Scholar
• Li J, Lee IW, Shin GH, et al. Curcumin-Eudragit® E PO solid dispersion: a simple and potent method to solve the problems of curcumin. Eur J Pharm Biopharm. 2015;94:322–332.
   PubMed Web of Science ®Google Scholar
• Forster A, Hempenstall J, Tucker Null, Rades T. The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion. Drug Dev Ind Pharm. 2001;27(6):549–560.
   PubMed Web of Science ®Google Scholar
• Meng F, Trivino A, Prasad D, et al. Investigation and correlation of drug polymer miscibility and molecular interactions by various approaches for the preparation of amorphous solid dispersions. Eur J Pharm Sci. 2015;71:12–24.
   PubMed Web of Science ®Google Scholar
• Trivino A, Gumireddy A, Meng F, et al. Drug-polymer miscibility, interactions, and precipitation inhibition studies for the development of amorphous solid dispersions for the poorly soluble anticancer drug flutamide. Drug Dev Ind Pharm. 2019;45(8):1277–1291.
   PubMed Web of Science ®Google Scholar
• Trasi NS, Taylor LS. Effect of additives on crystal growth and nucleation of amorphous flutamide. Crystal Growth Design. 2012;12(6):3221–3230.
   Web of Science ®Google Scholar
• Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691–1698.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhu J, Ma F, et al. Preparation and characterization of solid dispersions of dipyridamole with a carrier “Copolyvidonum Plasdone S-630". Drug Dev Ind Pharm. 2007;33(8):888–899.
   PubMed Web of Science ®Google Scholar
• Taniguchi C, Inoue R, Kawabata Y, et al. Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria. Int J Pharm. 2012;434(1-2):148–154.
   PubMedGoogle Scholar
• Zecevic D, Meier R, Daniels R, et al. Site specific solubility improvement using solid dispersions of HPMC-AS/HPC SSL - mixtures. Eur J Pharm Biopharm. 2014;87(2):264–270.
   PubMed Web of Science ®Google Scholar
• Al-Obaidi H, Buckton G. Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS. AAPS Pharm Sci Tech. 2009;10(4):1172–1177.
   PubMed Web of Science ®Google Scholar
• Vasanthavada M, Tong W-Q, Joshi Y, et al. Phase behavior of amorphous molecular dispersions II: role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res. 2005;22(3):440–448.
   PubMed Web of Science ®Google Scholar
• Wani RJ, Sharma P, Zhong HA, et al. Preparation and characterization of griseofulvin solid dispersions. Assay Drug Dev Technol. 2020;18(3):109–118.
   PubMed Web of Science ®Google Scholar
• Al-Obaidi H, Ke P, Brocchini S, et al. Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int J Pharm. 2011;419(1-2):20–27.
   PubMedGoogle Scholar
• Al-Obaidi H, Lawrence MJ, Al-Saden N, et al. Investigation of griseofulvin and hydroxypropylmethyl cellulose acetate succinate miscibility in ball milled solid dispersions. Int J Pharm. 2013;443(1-2):95–102.
   PubMedGoogle Scholar
• Al-Obaidi H, Lawrence MJ, Shah S, et al. Effect of drug-polymer interactions on the aqueous solubility of milled solid dispersions. Int J Pharm. 2013;446(1-2):100–105.
   PubMedGoogle Scholar
• Chiang P-C, Ran Y, Chou K-J, et al. Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery. AAPS PharmSciTech. 2012;13(2):713–722.
   PubMed Web of Science ®Google Scholar
• Roine J, Kaasalainen M, Peurla M, et al. Controlled dissolution of griseofulvin solid dispersions from electrosprayed enteric polymer micromatrix particles: physicochemical characterization and in vitro evaluation. Mol Pharm. 2015;12(7):2254–2264.
   PubMedGoogle Scholar
• Stachurek I, Pielichowski K. Preparation and thermal characterization of poly(ethylene oxide)/griseofulvin solid dispersions for biomedical applications. J Appl Polym Sci. 2009;111(4):1690–1696
   Web of Science ®Google Scholar
• Das S, Roy S, Yuvaraja K, et al. Solid dispersions: an approach to enhance the bioavailability of poorly water-soluble drugs. Int J Pharmacol Pharma Technol. 2011;11(2):518–527.
   Google Scholar
• Wegiel LA, Zhao Y, Mauer LJ, et al. Curcumin amorphous solid dispersions: the influence of intra and intermolecular bonding on physical stability. Pharm Dev Technol. 2014;19(8):976–986.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Baird JA, Taylor LS. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation-classification and comparison with crystallization tendency from undercooled melts. J Pharm Sci. 2010;99(9):3826–3838.
   PubMed Web of Science ®Google Scholar
• Meng F, Dave V, Chauhan H. Qualitative and quantitative methods to determine miscibility in amorphous drug-polymer systems. Eur J Pharm Sci. 2015;77:106–111.
   PubMed Web of Science ®Google Scholar
• Qian F, Huang J, Hussain MA. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci. 2010;99(7):2941–2947.
   PubMed Web of Science ®Google Scholar
• Fini A, Cavallari C, Ospitali F. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles. Eur J Pharm Biopharm. 2008;70(1):409–420.
   PubMed Web of Science ®Google Scholar
• Ewing AV, Clarke GS, Kazarian SG. Stability of indomethacin with relevance to the release from amorphous solid dispersions studied with ATR-FTIR spectroscopic imaging. Eur J Pharm Sci. 2014;60:64–71.
   PubMed Web of Science ®Google Scholar
• Dahlberg C, Dvinskikh SV, Schuleit M, et al. Polymer swelling, drug mobilization and drug recrystallization in hydrating solid dispersion tablets studied by multinuclear NMR microimaging and spectroscopy. Mol Pharm. 2011;8(4):1247–1256.
   PubMedGoogle Scholar
• Dahlberg C, Millqvist-Fureby A, Schuleit M, et al. Polymer-drug interactions and wetting of solid dispersions. Eur J Pharm Sci. 2010;39(1-3):125–133.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang X, Suwardie H, et al. Miscibility studies of indomethacin and Eudragit® E PO by thermal, rheological, and spectroscopic analysis. J Pharm Sci. 2012;101(6):2204–2212.
   PubMed Web of Science ®Google Scholar
• Priemel PA, Laitinen R, Grohganz H, et al. In situ amorphisation of indomethacin with Eudragit® E during dissolution. Eur J Pharm Biopharm. 2013;85(3 Pt B):1259–1265.
   PubMed Web of Science ®Google Scholar
• Cho Y, Ha E-S, Baek I-H, et al. Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® E. Molecules. 2015;20(6):9496–9509.
   PubMed Web of Science ®Google Scholar
• Patel BB, Patel JK, Chakraborty S. Solubility enhancement using poly(meth)acrylate based solid dispersions. Powder Technol. 2015;270:27–38.
   Web of Science ®Google Scholar
• Biswal S, Sahoo J, Murthy PN, et al. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS Pharm Sci Tech. 2008;9(2):563–570.
   PubMed Web of Science ®Google Scholar
• Lheritier J, Chauvet A, Abramovici B, et al. Improvement of the dissolution kinetics of SR 33557 by means of solid dispersions containing PEG 6000. Int J Pharm. 1995;123(2):273–279.
   Google Scholar
• Zerrouk N, Chemtob C, Arnaud P, et al. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm. 2001;225(1-2):49–62.
   PubMed Web of Science ®Google Scholar
• Bley H, Fussnegger B, Bodmeier R. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm. 2010;390(2):165–173.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Raina S, Hsieh Y-L, et al. Classification of the crystallization behavior of amorphous active pharmaceutical ingredients in aqueous environments. Pharm Res. 2014;31(4):969–982.
   PubMed Web of Science ®Google Scholar
• Alhalaweh A, Alzghoul A, Kaialy W, et al. Computational predictions of glass-forming ability and crystallization tendency of drug molecules. Mol Pharm. 2014;11(9):3123–3132.
   PubMedGoogle Scholar
• Pajula K, Taskinen M, Lehto V-P, et al. Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram. Mol Pharm. 2010;7(3):795–804.
   PubMedGoogle Scholar
• Pajula K, Lehto V-P, Ketolainen J, et al. Computational approach for fast screening of small molecular candidates to inhibit crystallization in amorphous drugs. Mol Pharm. 2012;9(10):2844–2855.
   PubMed Web of Science ®Google Scholar